Company news

CytomX Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

June 21, 2020

CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

May 28, 2020

CytomX Therapeutics to Participate at Upcoming Healthcare Conferences

May 27, 2020

CytomX Therapeutics to Host Conference Call and Webcast to Review ASCO ASCO20 Virtual Scientific Program Presentations

May 25, 2020

CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

May 12, 2020

CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

May 6, 2020

CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

May 4, 2020

CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

April 28, 2020

CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors

April 27, 2020

CytomX Therapeutics to Announce First Quarter 2020 Financial Results

April 26, 2020

CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

March 29, 2020

CytomX Therapeutics announces appointment of Carlos Campoy as chief financial officer

March 22, 2020

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

March 22, 2020

CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update

February 26, 2020

CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

February 24, 2020

Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

February 23, 2020

CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results

February 19, 2020

CytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical Officer

February 2, 2020

CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook

December 18, 2019

CytomX Therapeutics to Present at Upcoming Healthcare Conferences

November 10, 2019

CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

November 6, 2019

CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma

October 28, 2019

CytomX Therapeutics to Announce Third Quarter 2019 Financial Results

October 23, 2019

CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer

October 13, 2019

← Newer news releases

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.